Aldeyra Therapeutics, Inc.: updates and filings

ALDXNASDAQHealthcare · Pharmaceutical Preparations

Price

$0.84

November 20, 2026Market cap $51M

What Ploutos Investor adds for Aldeyra Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2013
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 36% since Nov 5, 2026, when the 10-Q these figures come from was filed ($0.62 then, $0.84 on Nov 20, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 27, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 17, 2026Delisting notice
    Form8-K
  • Nov 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 9, 2026Other material events
    Form8-K
  • Nov 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Sep 29, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 12, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jul 30, 2026Material agreement entered
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 15, 2026Other material events
    Form8-K
  • Jun 10, 2026Officer or director change, shareholder vote, Regulation FD disclosure
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 1, 2026Regulation FD disclosure
    Form8-K
  • Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 27, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 27, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 20, 2026Officer or director change
    Form8-K
  • Apr 1, 2026Other material events
    Form8-K
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 17, 2026Regulation FD disclosure, other material events
    Form8-K
  • Feb 27, 2026Shares registered for employees
    FormS-8
  • Feb 27, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 6, 2005.

The full analysis

What do Aldeyra Therapeutics's filings show?

The filings are where every one of Aldeyra Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.